What this is
- How it works
- How it works isn't classified yet
- Tested for
- B2 Thymoma, Thymic Carcinoma
- Main trialPhase 1/2
- “This Phase 1/2 study evaluates the safety, tolerability, and preliminary efficacy of target-selected CAR-natural killer (CAR-NK) cells in adults with relapsed or refractory B2 thymoma or thymic carcinoma. Participants undergo centralized tumor antigen assessment (CD30, CD5, and mesothelin). Based on the dominant and clinically actionable antigen expression profile, each participant is assigned to one of three parallel cohorts (CD30-CAR-NK, CD5-CAR-NK, or mesothelin-CAR-NK). All cohorts use the same lymphodepleting conditioning regimen followed by CAR-NK infusion(s).”In the company’s words, NCT07598955 on ClinicalTrials.gov
Other drugs for Thymic Carcinoma
- EB-CAR5-NKBeijing Biotech · Phase 1/2
- EB-CARMSLN-NKBeijing Biotech · Phase 1/2
- Sacituzumab tirumotecanKelun-Biotech · Merck & Co. · Phase 2
- KFA115Novartis · Phase 1
Coming up1
- 14 Jun 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 14 Jun 2027 | Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026